Raymond James Maintains Outperform on NGM Biopharmaceuticals, Raises Price Target to $6

Raymond James analyst Steven Seedhouse maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Outperform and raises the price target from $4 to $6.

Raymond James analyst Steven Seedhouse maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Outperform and raises the price target from $4 to $6.

Total
0
Shares
Related Posts